The new plant of Indian Immunologicals Limited (IIL) at Karkapatla in Hyderabad is set to become India’s largest producer of essential human vaccines and animal health formulations in the country.
As part of its expansion plans, the company has invested about Rs. 250 crores to set up the state-of-art facility with a large manufacturing capacity to meet the growing demand for vaccines in the next 10 years.
“This unit at phase III of Genome Valley, Karkapatla is IIL’s second manufacturing unit in Hyderabad. Spread across 47 acres area, the plant will significantly expand IIL’s manufacturing capabilities. The new facility has been established to manufacture vaccines against infectious diseases of humans and animal health formulations catering to domestic as well as international market,” informed Dr. K. Anand kumar, deputy managing director, IIL.
IIL had developed this facility considering the growing demand for the next 10 years for human vaccines and animal health formulations. Human vaccine facility has been established to meet all WHO pre-qualification standards. The first phase of human vaccine facility has the capacity to produce 8 million doses of human rabies vaccine. The animal health formulation facility is equipped to produce an estimated capacity of 300 million tablets, 100 million bolus, and 20 million vials of injectables.
The plant is equipped with cutting-edge German technology and has fully automated systems consisting of automated granulation, compression lines which have the least possible human intervention. This will become India’s largest facility for producing animal health formulations. The facility currently equipped to manufacture rabies vaccine for humans and produces new animal health formulations for bovines, sheep and pets. The unit will provide direct employment to 150 and indirect employment to 300 people.
“The facility will strengthen IIL’s position in the industry and will immensely increase our manufacturing capabilities. We are expecting this plant to play a key role in manufacturing top quality vaccines with the most recent German technology. We will strive to maintain our industry leadership in providing the vaccines in the most affordable prices without compromising on the quality,” added Dr. Kumar.
With the new addition, IIL has 5 manufacturing facilities at various locations - Ooty – anti rabies production unit; Rajkot, Gujarat – cattle feed unit; Hyderabad, Gachibowli – biologicals unit; New Zealand – overseas serum manufacturing unit. IIL currently employs around 1300 people.